Equities research analysts expect that Amarin Co. plc (NASDAQ:AMRN) will post earnings per share of ($0.07) for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Amarin Co. plc’s earnings. Amarin Co. plc posted earnings of ($0.15) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 53.3%. The company is expected to report its next quarterly earnings results on Thursday, May 4th.
According to Zacks, analysts expect that Amarin Co. plc will report full-year earnings of ($0.21) per share for the current year, with EPS estimates ranging from ($0.29) to ($0.17). For the next financial year, analysts anticipate that the company will report earnings of $0.03 per share, with EPS estimates ranging from ($0.15) to $0.24. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Amarin Co. plc.
Amarin Co. plc (NASDAQ:AMRN) last released its earnings results on Tuesday, February 28th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.09) by $0.04. The business earned $38.40 million during the quarter, compared to analyst estimates of $36.13 million. The business’s quarterly revenue was up 45.5% compared to the same quarter last year. During the same period last year, the business earned ($0.10) EPS.
A number of equities research analysts have weighed in on AMRN shares. Cantor Fitzgerald set a $6.00 target price on Amarin Co. plc and gave the company a “buy” rating in a report on Thursday, March 2nd. Zacks Investment Research raised Amarin Co. plc from a “sell” rating to a “hold” rating in a report on Tuesday, February 28th. Jefferies Group LLC set a $5.00 target price on Amarin Co. plc and gave the company a “buy” rating in a report on Tuesday, February 28th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Amarin Co. plc in a report on Tuesday, January 24th. Five research analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and a consensus target price of $5.90.
WARNING: “Brokerages Anticipate Amarin Co. plc (AMRN) Will Announce Earnings of -$0.07 Per Share” was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://sportsperspectives.com/2017/04/21/brokerages-anticipate-amarin-co-plc-amrn-will-announce-earnings-of-0-07-per-share.html.
Amarin Co. plc (NASDAQ:AMRN) traded down 0.31% during mid-day trading on Tuesday, reaching $3.17. The company’s stock had a trading volume of 676,921 shares. The stock’s market cap is $862.43 million. Amarin Co. plc has a 52-week low of $1.50 and a 52-week high of $3.65. The company has a 50 day moving average of $3.19 and a 200-day moving average of $3.17.
Several large investors have recently modified their holdings of AMRN. Consonance Capital Management LP acquired a new stake in shares of Amarin Co. plc during the third quarter worth $78,641,000. Baker BROS. Advisors LP acquired a new stake in shares of Amarin Co. plc during the third quarter worth $65,811,000. Rock Springs Capital Management LP acquired a new stake in shares of Amarin Co. plc during the third quarter worth $15,809,000. J. Goldman & Co LP increased its stake in shares of Amarin Co. plc by 31.9% in the fourth quarter. J. Goldman & Co LP now owns 1,077,200 shares of the biopharmaceutical company’s stock worth $3,318,000 after buying an additional 260,500 shares in the last quarter. Finally, Renaissance Technologies LLC increased its stake in shares of Amarin Co. plc by 662.8% in the fourth quarter. Renaissance Technologies LLC now owns 386,000 shares of the biopharmaceutical company’s stock worth $1,189,000 after buying an additional 335,400 shares in the last quarter. 39.07% of the stock is currently owned by hedge funds and other institutional investors.
About Amarin Co. plc
Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amarin Co. plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin Co. plc and related companies with MarketBeat.com's FREE daily email newsletter.